Learning Objectives
At the conclusion of this activity, participants will be able to:
  • Explore the evolution of SGLT2 inhibition in the CVOT era and evaluate mechanisms linking T2D and heart failure (HF).
  • Appraise new and emerging CVOT data for antihyperglycemic agents and compare outcomes data across the type 2 diabetes (T2D) therapeutic classes.
  • Examine recently-reported CVOT data for SGLT2 inhibitors, and discuss ways that these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients.
  • Using a case-based format, recognize opportunities for cardiologists to collaborate with endocrinologists, primary care providers, and other members of the healthcare team, and identify key characteristics of an integrated approach to HF management.